First, in NSCLC cell lines, ERK1/2 inhibition by siRNA or small-molecular inhibitors down-regulates the protein level of YAP, and in turn suppresses transcriptional activity of the Hippo pathway. The gene discussed is MAPK3; the disease is non-small cell lung carcinoma.